The FDA approved Beovu for the treatment of diabetic macular edema, Novartis announced in a press release.
This new indication follows the previous approval of Beovu (brolucizumab, Novartis) 6 mg for wet age-related macular degeneration in 2019 and was based on 1-year data from the phase 3 KESTREL and KITE clinical trials comparing the efficacy and safety of brolucizumab with aflibercept. According to Carl D. Regillo, MD, an investigator in both trials, Beovu is a “welcome addition to the current anti-VEGF treatment options in managing DME.”
“Having brolucizumab FDA approved